※関連の医療情報レポート

1. 腫瘍壊死因子関連アポトーシス誘導リガンド受容体2アゴニストのパイプライン・インサイト2016
   DIMR2016678 / DelveInsight / 2016年版 / 本調査レポートでは、世界における腫瘍壊死因子関連アポトーシス誘導リガンド受容体2アゴニストのパイプライン動向について調査・分析し、以下の構成でお届けいたします。 ・腫瘍壊死因子関連アポトーシス誘導リガンド受容体2アゴニストの概要 ・腫瘍壊死因子関連アポトーシス誘導リガンド受容体2アゴニストのパイプライン概要 ・企業別開発中の腫瘍壊死因子関連アポトーシス誘導リガンド受容体2アゴニスト ・後期治験段階の薬剤(Filed & Phase III)：比較分析 ・中期治験段階の薬剤(Phase II)：比較分析...SUMMARY DelveInsight’s, “TRAIL Receptor 2 (TRAIL-R2 or Death Receptor 5 or DR5) Agonists-Pipeline Insights, 2016”, report provides in depth insights on the pipeline drugs and their development activities around the TRAIL Receptor 2 (TRAIL-R2 or Death Receptor 5 or DR5) Agonists. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant...
2. 腫瘍壊死因子関連アポトーシス誘導リガンド受容体アゴニストのパイプライン・インサイト2016
   DIMR2016679 / DelveInsight / 2016年版 / 本調査レポートでは、世界における腫瘍壊死因子関連アポトーシス誘導リガンド受容体アゴニストのパイプライン動向について調査・分析し、以下の構成でお届けいたします。 ・腫瘍壊死因子関連アポトーシス誘導リガンド受容体アゴニストの概要 ・腫瘍壊死因子関連アポトーシス誘導リガンド受容体アゴニストのパイプライン概要 ・企業別開発中の腫瘍壊死因子関連アポトーシス誘導リガンド受容体アゴニスト ・後期治験段階の薬剤(Filed & Phase III)：比較分析 ・中期治験段階の薬剤(Phase II)：比較分析...SUMMARY DelveInsight’s, “TRAIL Receptor Agonists-Pipeline Insights, 2016”, report provides in depth insights on the pipeline drugs and their development activities around the TRAIL Receptor Agonists. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for TRAIL Receptor Agonists. DelveInsight’s Report also assesses...
3. TRAIL Receptor 1 (TRAIL-R1 or Death Receptor 4 or DR4) Agonists：アゴニストのグローバル市場2014（薬開発、治験動向）
   DIMR2014678 / DelveInsight / 2014年版 / ...DelveInsight’s,“TRAIL Receptor 1 (TRAIL-R1 or Death Receptor 4 or DR4) Agonists-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the pipeline drugs that fall under TRAIL Receptor 1 (TRAIL-R1 or Death Receptor 4 or DR4) Agonists. This report provides information on the therapeutic development based on the TRAIL Receptor 1 (TRAIL-R1 or Death Receptor 4 or DR4) Agonists dealing with mechanism of action, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery...
4. TRAIL Receptor 2 (TRAIL-R2 or Death Receptor 5 or DR5) Agonists：アゴニストのグローバル市場2014（薬開発、治験動向）
   DIMR2014679 / DelveInsight / 2014年版 / ...DelveInsight’s,“TRAIL Receptor 2 (TRAIL-R2 or Death Receptor 5 or DR5) Agonists-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the pipeline drugs that fall under TRAIL Receptor 2 (TRAIL-R2 or Death Receptor 5 or DR5) Agonists. This report provides information on the therapeutic development based on the TRAIL Receptor 2 (TRAIL-R2 or Death Receptor 5 or DR5) Agonists dealing with mechanism of action, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery...
5. TRAIL Receptor 1 (TRAIL-R1 or Death Receptor 4 or DR4) Agonists：アゴニストのグローバル市場2015（薬開発、治験動向）
   DIMRMOA5678 / DelveInsight / 2015年版 / ...DelveInsight’s,“TRAIL Receptor 1 (TRAIL-R1 or Death Receptor 4 or DR4) Agonists-Pipeline Insights, 2015”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the pipeline drugs that fall under TRAIL Receptor 1 (TRAIL-R1 or Death Receptor 4 or DR4) Agonists. This report provides information on the therapeutic development based on the TRAIL Receptor 1 (TRAIL-R1 or Death Receptor 4 or DR4) Agonists dealing with mechanism of action, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery...
6. TRAIL Receptor 2 (TRAIL-R2 or Death Receptor 5 or DR5) Agonists：アゴニストのグローバル市場2015（薬開発、治験動向）
   DIMRMOA5679 / DelveInsight / 2015年版 / ...DelveInsight’s,“TRAIL Receptor 2 (TRAIL-R2 or Death Receptor 5 or DR5) Agonists-Pipeline Insights, 2015”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the pipeline drugs that fall under TRAIL Receptor 2 (TRAIL-R2 or Death Receptor 5 or DR5) Agonists. This report provides information on the therapeutic development based on the TRAIL Receptor 2 (TRAIL-R2 or Death Receptor 5 or DR5) Agonists dealing with mechanism of action, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery...
7. Tie-2受容体アゴニストのパイプライン・インサイト2016
   DIMR2016664 / DelveInsight / 2016年版 / 本調査レポートでは、世界におけるTie-2受容体アゴニストのパイプライン動向について調査・分析し、以下の構成でお届けいたします。 ・Tie-2受容体アゴニストの概要 ・Tie-2受容体アゴニストのパイプライン概要 ・企業別開発中のTie-2受容体アゴニスト ・後期治験段階の薬剤(Filed & Phase III)：比較分析 ・中期治験段階の薬剤(Phase II)：比較分析...SUMMARY DelveInsight’s, “Tie-2 Receptor Agonists-Pipeline Insights, 2016”, report provides in depth insights on the pipeline drugs and their development activities around the Tie-2 Receptor Agonists. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Tie-2 Receptor Agonists. DelveInsight’s Report also assesses...
8. ビタミンD受容体アゴニストのパイプライン・インサイト2016
   DIMR2016713 / DelveInsight / 2016年版 / 本調査レポートでは、世界におけるビタミンD受容体アゴニストのパイプライン動向について調査・分析し、以下の構成でお届けいたします。 ・ビタミンD受容体アゴニストの概要 ・ビタミンD受容体アゴニストのパイプライン概要 ・企業別開発中のビタミンD受容体アゴニスト ・後期治験段階の薬剤(Filed & Phase III)：比較分析 ・中期治験段階の薬剤(Phase II)：比較分析...SUMMARY DelveInsight’s, “Vitamin D Receptor (VDR or Calcitriol Receptor) Agonists-Pipeline Insights, 2016”, report provides in depth insights on the pipeline drugs and their development activities around the Vitamin D Receptor (VDR or Calcitriol Receptor) Agonists. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over...
9. AMPA受容体アゴニストのパイプライン・インサイト2016
   DIMR201675 / DelveInsight / 2016年版 / 本調査レポートでは、世界におけるAMPA受容体アゴニストのパイプライン動向について調査・分析し、以下の構成でお届けいたします。 ・AMPA受容体アゴニストの概要 ・AMPA受容体アゴニストのパイプライン概要 ・企業別開発中のAMPA受容体アゴニスト ・後期治験段階の薬剤(Filed & Phase III)：比較分析 ・中期治験段階の薬剤(Phase II)：比較分析...SUMMARY DelveInsight’s, “AMPA Receptor Agonists-Pipeline Insights, 2016”, report provides in depth insights on the pipeline drugs and their development activities around the AMPA Receptor Agonists. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for AMPA Receptor Agonists. DelveInsight’s Report also assesses...
10. NMDA受容体アゴニストのパイプライン・インサイト2016
    DIMR2016510 / DelveInsight / 2016年版 / 本調査レポートでは、世界におけるNMDA受容体アゴニストのパイプライン動向について調査・分析し、以下の構成でお届けいたします。 ・NMDA受容体アゴニストの概要 ・NMDA受容体アゴニストのパイプライン概要 ・企業別開発中のNMDA受容体アゴニスト ・後期治験段階の薬剤(Filed & Phase III)：比較分析 ・中期治験段階の薬剤(Phase II)：比較分析...SUMMARY DelveInsight’s, “NMDA Receptor Agonists-Pipeline Insights, 2016”, report provides in depth insights on the pipeline drugs and their development activities around the NMDA Receptor Agonists. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for NMDA Receptor Agonists. DelveInsight’s Report also assesses...